Aileen Y Zhou from San Francisco, CA, age 60

Resumes

Research Manager

view source

Location:

San Francisco, CA

Industry:

Information Services

Work:

Guidepoint
Research Manager
Disrupthr San Francisco Bay Area
Digital Marketing Coordinator
Young Enterprise Trust Nov 2014 - Sep 2016
Mentor
Auckland Council Jul 2014 - Sep 2016
Youth Advisory Panel Youth Representative
International Connector Jul 2014 - Sep 2016
Millennial Catalyst

Education:

Babson College 2019
Bachelors, Bachelor of Science, Management, Business Management, Entrepreneurship Babson Leadership Academy Jul 2017
Singapore Management University

Skills:

Leadership
Business Strategy
Public Speaking
Communication
Event Planning
Online Advertising
Public Relations
Social Media Marketing
Nonprofits
Strategy
Management
Consulting

Languages:

Mandarin
English
Spanish

Certifications:

The Challenges of Global Health
Talent Management
Talent Sourcing
Strategic Human Resources
Coursera Course Certificates, License Gjdzzpu2Zspx
License Gjdzzpu2Zspx

Aileen Zhou

view source

Location:

Seattle, WA

Industry:

Food Production

Education:

Nanjing Agricultural University 1982 - 1986
Bachelors

San Francisco En Omgeving, Verenigde Staten

view source

Location:

San Francisco, CA

Industry:

Biotechnology

Work:

San Francisco En Omgeving, Verenigde Staten

Skills:

Protein Chemistry
Cell Culture
Gel Electrophoresis
Assay Development
High Throughput Screening
Validation
Characterization
Microfluidics
Molecular Biology
Biotechnology
Elisa
Lifesciences
Purification
Protein Purification
Drug Discovery
Protein Expression
Immunology
Sds Page
Qpcr
Western Blotting
Antibodies
Life Sciences
Cancer
Biochemistry
Cell
Biopharmaceuticals
Hardware Diagnostics
Genetics
Enzyme Kinetics
Dna
Cell Biology
Oncology
Enzyme Assays

Languages:

Mandarin

Us Patents

Methods For Prevention Of Surface Adsorption Of Biological Materials To Capillary Walls In Microchannels
view source
US Patent:

7252928, Aug 7, 2007
Filed:

Feb 25, 2003
Appl. No.:

10/374759
Inventors:

Dean G. Hafeman - Hillsborough CA, US
Aileen Zhou - San Leandro CA, US
Assignee:

Caliper Life Sciences, Inc. - Mountain View CA
International Classification:

G01N 27/26
US Classification:

435 4, 435325, 204454, 204450, 204451, 977904, 977920
Abstract:

Methods for reducing surface adsorption of biological materials to the walls of microfluidic conduits in microscale devices are provided. In an example of the methods, one or more colloidal-size particles, such as colloidal silica particles, are flowed in a fluid within the microfluidic conduit in the presence of one or more adherent biological materials (such as one or more proteins, cells, carbohydrates, nucleic acids, lipids and the like) to adsorb to the materials and prevent them from binding to the capillary walls of the microfluidic conduit. Other adsorption inhibition agents such as detergents and nonaqueous solvents can be used alone or in combination with colloidal particles to reduce surface adsorption in microfluidic conduits.

Methods For Removing Biological Residue From Capillary Walls In Microchannels
view source
US Patent:

7901621, Mar 8, 2011
Filed:

Jul 2, 2007
Appl. No.:

11/772744
Inventors:

Dean G. Hafeman - Hillsborough CA, US
Aileen Zhou - San Leandro CA, US
Assignee:

Caliper Life Sciences, Inc. - Mountain View CA
International Classification:

A61L 2/02
US Classification:

422 28, 422 1, 516 77, 516 80
Abstract:

Methods for removing a residue of one or more biological materials deposited on the walls of a microfluidic conduit in microscale devices are provided. In an example of the methods, one or more colloidal-size particles, such as colloidal silica particles, are flowed in a fluid within the microfluidic conduit having residues of materials previously deposited on the walls thereof to adsorb to the materials and to remove such deposits from the walls of the microfluidic conduit.

Compositions And Methods Of Use For Mgd-Csf In Disease Treatment
view source
US Patent:

8178109, May 15, 2012
Filed:

Feb 12, 2009
Appl. No.:

12/370559
Inventors:

Dirk Behrens - San Francisco CA, US
Elizabeth Bosch - San Francisco CA, US
Stephen K. Doberstein - San Francisco CA, US
Robert Forgan Halenbeck - San Francisco CA, US
Kevin Hestir - San Francisco CA, US
Min Mei Huang - San Francisco CA, US
Ernestine Lee - San Francisco CA, US
Haishan Lin - San Francisco CA, US
Thomas Linnemann - San Francisco CA, US
Shannon Marshall - San Francisco CA, US
Justin G. P. Wong - San Francisco CA, US
Ge Wu - La Canada CA, US
Aileen Zhou - San Francisco CA, US
Cindy Leo - San Francisco CA, US
Lewis T. Williams - San Francisco CA, US
Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA
International Classification:

A61K 39/00
US Classification:

4241981
Abstract:

Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions And Methods Of Use For Mgd-Csf In Disease Treatment
view source
US Patent:

8575312, Nov 5, 2013
Filed:

Apr 13, 2012
Appl. No.:

13/446254
Inventors:

Dirk Behrens - San Francisco CA, US
Elizabeth Bosch - San Francisco CA, US
Stephen K. Doberstein - San Francisco CA, US
Robert Forgan Halenbeck - San Francisco CA, US
Kevin Hestir - San Francisco CA, US
Min Mei Huang - San Francisco CA, US
Ernestine Lee - San Francisco CA, US
Haishan Lin - San Francisco CA, US
Thomas Linnemann - San Francisco CA, US
Shannon Marshall - San Francisco CA, US
Justin G. P. Wong - San Francisco CA, US
Ge Wu - San Francisco CA, US
Aileen Zhou - San Francisco CA, US
Cindy Leo - San Francisco CA, US
Lewis T. Williams - San Francisco CA, US
Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA
International Classification:

C07K 14/00
US Classification:

530351
Abstract:

Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions And Methods Of Use For Mgd-Csf In Disease Treatment
view source
US Patent:

20070264277, Nov 15, 2007
Filed:

Jul 21, 2005
Appl. No.:

11/632319
Inventors:

Dirk Behrens - San Francisco CA, US
Elizabeth Bosch - San Francisco CA, US
Stephen Doberstein - San Francisco CA, US
Robert Halenbeck - San Francisco CA, US
Kevin Hestir - San Francisco CA, US
Min Huang - San Francisco CA, US
Ernestine Lee - San Francisco CA, US
Haishan Lin - San Francisco CA, US
Thomas Linnemann - San Francisco CA, US
Shannon Marshall - San Francisco CA, US
Justin Wong - San Francisco CA, US
Ge Wu - San Francisco CA, US
Aileen Zhou - San Francisco CA, US
International Classification:

A61K 39/00
A61K 38/00
C07H 21/00
C07K 14/00
C07K 16/18
C12N 15/00
C12N 15/87
C12N 5/06
C12P 1/00
G01N 33/53
US Classification:

424185100, 435320100, 435325000, 435375000, 435466000, 435069100, 435007100, 514002000, 530350000, 530387100, 536023100
Abstract:

Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Bioassay For T-Cell Co-Stimulatory Proteins Containing Fc Domains
view source
US Patent:

20220348657, Nov 3, 2022
Filed:

Apr 17, 2020
Appl. No.:

17/604505
Inventors:

- South San Francisco CA, US
Artur KARASYOV - Oakland CA, US
Zheng MENG - Burlingame CA, US
Shawn RUSSELL - Waltham MA, US
Nathan SALLEE - San Francisco CA, US
Hongbing ZHANG - Albany CA, US
Aileen ZHOU - Brisbane CA, US
International Classification:

C07K 16/28
C07K 14/705
G01N 33/554
Abstract:

Provided herein are components (e.g., cells and soluble proteins), systems, and methods for assessing the biological activity of soluble proteins comprising an Fc domain and a CD28-binding domain (e.g., CD80 extracellular domain Fc fusion proteins).